14-day Premium Trial Subscription Sign Up For FreeGet Free

When Should You SELL Your Stocks? Click to watch.

Catalyst Biosciences Stock Forecast


$0.38 (0%)

Volume: 67.878k

Closed: May 20, 2022

Hollow Logo Score: -3.658

Catalyst Biosciences Stock Forecast

$0.38 (0%)

Volume: 67.878k

Closed: May 20, 2022

Score Hollow Logo -3.658

Catalyst Biosciences Company Profile

260 Littlefield Avenue

South San Francisco CA 94080



Industry: Biotechnology

Sector: Healthcare

Catalyst Biosciences


Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on engineering proteases as therapeutics for hemophilia, hemeostasis, complement-mediated diseases, and other unmet medical needs. Its product pipeline includes CB 813d, a Factor VIIa drug candidate that completed a Phase I clinical trials evaluating safety and tolerability, as well as pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with and without inhibitors. The company’s preclinical development stage drugs comprise CB 2679d/ISU 304, a next-generation Factor IX drug for the treatment of patients with hemophilia B; and a Factor Xa variant. It is also developing CB 2782, an anti-C3 inflammation development candidate for the treatment of delayed graft function in kidney transplants; and an ophthalmic anti-C3 candidate for treatment of dry age-related macular degeneration. The company has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. Catalyst Biosciences, Inc. is headquartered in South San Francisco, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE